Our expert for hiPSC derived cardiac cells, and cell-based assays & services for drug safety and efficacy screenings
The use of Cor.4U® and Pluricyte® Cardiomyocytes in combination with the FDSS/µCell instrument has been optimized in house. Combining these technologies enables the evaluation of potential cardiotoxic effects of compounds at high-throughput (up to 384 wells), thereby supporting your decision making in the safety of drug candidates at an early stage of drug development.
You can find a step-by-step description of the analysis of fluorescent dye-based calcium transients of our hiPSC-derived cardiomyocytes using the FDSS/µCell System in our User Guides:
Case studies were performed to assess the acute effects of well-known cardioactive compounds in Cor.4U® and Pluricyte® Cardiomyocytes calcium transients using the FDSS/mCELL kinetic plate reader. Acute effects of cardioactive compounds were determined to analyze various parameters, including peak frequency, peak amplitudes, peak slopes, and average peak width duration. Below an example is shown of the effect of the reference compound, astemizole, in Cor4U® cardiomyocytes.
Cor.4U® show reduced peak frequency and arrhythmia in response to astemizole
Astemizole is a hERG channel blocker that can induce arrhythmias at higher concentrations. Treatment of Cor.4U® cardiomyocytes with increasing concentrations of astemizole result in decreased peak frequency (middle panel) and arrhythmia (bottom panel) of the calcium transients after 30 minutes of incubation.
You can find the complete study in our application notes: